Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule belonging to the naphthalenecarboxylic acids and derivatives class. It features a naphthalene moiety with hydroxy, methoxy, and methyl substitutions and is esterified with a meso–dihydroxy cyclopentenyl group. The compound has been identified as an experimental agent that targets the protein neocarzinostatin—a chromoprotein antibiotic known for its antitumor activity—suggesting potential use in research related to neocarzinostatin or as a model ligand for studying protein-ligand interactions. There are no approved clinical indications or marketed products containing this molecule[1][3][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2-hydroxy-7-methoxy-5-methyl-naphthalene-1-carboxylic acid meso-2,5-dihydroxy-cyclopent-3-enyl ester.